News Release: Minnesota begins screening newborns for Krabbe disease

Minnesota begins screening newborns for Krabbe disease Minnesota's Newborn Screening Program began universal screening today for Krabbe disease. As technology and treatments have improved in recent decades, Minnesota has expanded its newborn screening panel to help detect more disorders.  "Minnesota has one of the most comprehensive newborn screening programs in the country," said Minnesota Commissioner of Health Dr. Brooke Cunningham. "Adding Krabbe disease to the long list of conditions the lab already screens for will help identify more children earlier, slow the progression of their symptoms and even increase their lifespan." Krabbe disease is a rare, genetic condition in which the newborn cannot fully break down certain fats. These fats build up in the body and can lead to damage to the nerves affecting a person's ability to eat, walk and speak. In the most severe form, infantile Krabbe disease, symptoms can progress to death within the first two years of life. There is no cure for Krabbe disease, but treatment can help manage symptoms and improve quality of life. Currently, the only treatment is a stem cell transplant, which is ideally performed before a baby identified with infantile Krabbe disease is 30 days old. Due to the importance of early treatment, the process from screening to diagnostic exams and treatment must move quickly.  Identifying infantile Krabbe disease in newborns allows families to receive early diagnosis and monitoring, education and appropriate medical care. When newborn screening identifies a baby at risk for infantile Krabbe disease, the family is referred by their doctor to metabolic specialists at M Health Fairview, which is currently the only center in the region equipped to perform stem cell transplants in newborns. In August 2023, Commissioner Cunningham approved the Newborn Screening Advisory Committee's recommendation to add Krabbe disease to the list of conditions for which Minnesota newborns are routinely screened. Since then, the Minnesota Department of Health (MDH) Newborn Screening Program has been working diligently to prepare for screening by validating a testing method, working with partners across the state. Since 1964 when Minnesota started screening for PKU (phenylketonuria), blood samples from all Minnesota newborns have been sent to MDH's Public Health Lab for screening unless their parents opt out. The lab now screens all babies born in Minnesota for more than 60 conditions. In 2023, the lab screened more than 60,400 newborns from across the state and recommended early intervention and treatment for conditions detected in about 400 of them. When a condition is detected, MDH contacts the child's health care provider to discuss the result, educate them about the condition and review the recommended follow-up.  More information about newborn screening is available on the MDH website at Newborn Screening Program. -MDH-  Media inquiries: Amy Barrett MDH Communications  651-201-4993 amy.barrett@state.mn.us You can update or cancel your subscription at any time by editing your personal profile. You will need your email address and your password (if you have selected one). P.S. If you have any questions or problems please contact subscriberhelp.govdelivery.com for assistance.  STAY CONNECTED:   MDH on X     MDH on Facebook     MDH on LinkedIn   MDH on Instagram   This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: Minnesota Department of Health · 625 Robert Street North · St. Paul MN 55155 · 651-201-5000